Evidence mapPaperPMID 40882001Full record

Trial reportDiabetes care2025

Impact of Parental or First-Degree Family History of Diabetes on Diabetes Incidence and Progression During Long-term Follow-up in the Diabetes Prevention Program Outcomes Study.

Samuel Dagogo-Jack, Erin J Kazemi, Lindsay Doherty, Preethi Srikanthan, Justin B Echouffo-Tcheugui, William C Knowler, Steven E Kahn, Sunder Mudaliar, Marinella Temprosa, DPP Research Group

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samuel Dagogo-JackDivision of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN.ORCID 0000-0001-5318-9677
Erin J KazemiCoordinating Center, Biostatistics Center, The George Washington University, Rockville, MD.
Lindsay DohertyCoordinating Center, Biostatistics Center, The George Washington University, Rockville, MD.
Preethi SrikanthanDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Justin B Echouffo-TcheuguiJohns Hopkins University School of Medicine, Baltimore, MD.
William C KnowlerCoordinating Center, Biostatistics Center, The George Washington University, Rockville, MD.
Steven E KahnDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, and VA Puget Sound Health Care System, Seattle, WA.
Sunder MudaliarUniversity of California, San Diego, San Diego, CA.
Marinella TemprosaCoordinating Center, Biostatistics Center, The George Washington University, Rockville, MD.ORCID 0000-0002-9976-745X
DPP Research Group

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · GEORGE WASHINGTON UNIVERSITY · 1994 to 2005
$23.7M
Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
Physical activity, physical function, and frailty in relation to cognitive impairment and AD/ADRD biomarkers in DPPOSU19AG078558 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$15.5M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
UAB Nutrition Obesity Research Center (NORC)P30DK056336 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2000 to 2025
$6.0M
Post-DDP Follow-up StudyU01DK048413 · UNIVERSITY OF WASHINGTON · 1994 to 2005
$4.4M
Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Biostatistics CenterU01DK094176 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Ionut Bebu, Barbara Halina Braffett · 2022 to 2022
$4.3M
TITLE OMITTEDU01DK048349 · YESHIVA UNIVERSITY · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIALU01DK048443 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2005
$3.8M
Post-DPP Follow-up StudyU01DK048485 · JOHNS HOPKINS UNIVERSITY · 1994 to 2005
$3.7M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1994 to 2005
$3.6M
National Institutes of Health (NIH) DK-55433National Institutes of Health (NIH) DK-55564NHLBI NIH HHS K23 HL153774NIA NIH HHS U19 AG078558NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK056336NIDDK NIH HHS R01 DK067269NIDDK NIH HHS R01 DK128129NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048349NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048377NIDDK NIH HHS U01 DK048380NIDDK NIH HHS U01 DK048381NIDDK NIH HHS U01 DK048387NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048406NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048411NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048434NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048468NIDDK NIH HHS U01 DK048485NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01 DK048514NIDDK NIH HHS U01 DK094176NIDDK NIH HHS U01 DK098246NIH HHS U01 DK048339NIH HHS U01 DK048349NIH HHS U01 DK048375NIH HHS U01 DK048377NIH HHS U01 DK048380NIH HHS U01 DK048381NIH HHS U01 DK048387NIH HHS U01 DK048397NIH HHS U01 DK048400NIH HHS U01 DK048404NIH HHS U01 DK048406NIH HHS U01 DK048407NIH HHS U01 DK048411NIH HHS U01 DK048412NIH HHS U01 DK048413NIH HHS U01 DK048434NIH HHS U01 DK048437NIH HHS U01 DK048443NIH HHS U01 DK048468NIH HHS U01 DK048485NIH HHS U01 DK048489NIH HHS U01 DK048514
6 · The paper itself

Abstract

objectiveTo determine the effects of first-degree family history of diabetes on diabetes incidence in Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) participants. RESEARCH DESIGN AND

methodsIn the DPP, adults with prediabetes were randomized to an intensive lifestyle intervention, metformin, or placebo and followed for incident diabetes. On study completion 88% of eligible DPP participants reenrolled in DPPOS for long-term follow-up. The present analysis includes all 3,072 participants with family history information through DPPOS, with a median follow-up of 21 years (1,975 had parental history of diabetes [PH] [312 biparental, 947 maternal, 716 paternal], 226 had only sibling history [SH], and 871 denied any family history). The primary outcome is incident diabetes based on American Diabetes Association criteria, with adjustment for demographic and clinical variables, DPP randomization arm, and polygenic risk score (PRS).

resultsAdjusted hazard ratio (HR) was 1.21 (95% CI 1.06, 1.38) for any family history, 1.19 (1.04, 1.35) for PH, and 1.15 (0.91, 1.44) for SH. Biparental history conferred greater hazard (HR 1.44 [95% CI 1.22, 1.69]) than maternal (1.22 [1.08, 1.38]) or paternal (1.22 [1.08, 1.39]) diabetes history alone. PRS explained 32% of the association of any family history with diabetes risk.

conclusionsPH increased type 2 diabetes risk after DPP treatment group was controlled for. That effect was only partially explained by PRS, suggesting that rare gene variants, familial, and environmental factors may contribute to type 2 diabetes risk in people with prediabetes.

Indexed as

Diabetes Mellitus, Type 2AdultFemaleFollow-Up StudiesHumansIncidenceMaleMetforminMiddle AgedPrediabetic StateMetformin

Identifiers

PMID40882001
PMCPMC12451838

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.